PT3230316T - Ratamento de degenerescência macular relacionada com a idade com uma pequena lesão de neovascularização coroideia ativa - Google Patents

Ratamento de degenerescência macular relacionada com a idade com uma pequena lesão de neovascularização coroideia ativa

Info

Publication number
PT3230316T
PT3230316T PT158199653T PT15819965T PT3230316T PT 3230316 T PT3230316 T PT 3230316T PT 158199653 T PT158199653 T PT 158199653T PT 15819965 T PT15819965 T PT 15819965T PT 3230316 T PT3230316 T PT 3230316T
Authority
PT
Portugal
Prior art keywords
treatment
macular degeneration
related macular
choroidal neovascularization
age related
Prior art date
Application number
PT158199653T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55069121&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3230316(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/CN2014/093548 external-priority patent/WO2016090590A1/en
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of PT3230316T publication Critical patent/PT3230316T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PT158199653T 2014-12-11 2015-12-10 Ratamento de degenerescência macular relacionada com a idade com uma pequena lesão de neovascularização coroideia ativa PT3230316T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2014/093548 WO2016090590A1 (en) 2014-12-11 2014-12-11 Treatment of age related macular degeneration with a small active choroidalneovascularizationlesion
CN2015089251 2015-09-09

Publications (1)

Publication Number Publication Date
PT3230316T true PT3230316T (pt) 2022-02-24

Family

ID=55069121

Family Applications (1)

Application Number Title Priority Date Filing Date
PT158199653T PT3230316T (pt) 2014-12-11 2015-12-10 Ratamento de degenerescência macular relacionada com a idade com uma pequena lesão de neovascularização coroideia ativa

Country Status (16)

Country Link
US (2) US20170326106A1 (https=)
EP (2) EP3985023A1 (https=)
JP (3) JP7320919B2 (https=)
CN (3) CN114306575A (https=)
AU (4) AU2015360496B2 (https=)
CA (1) CA2970315C (https=)
DK (1) DK3230316T3 (https=)
ES (1) ES2907148T3 (https=)
HR (1) HRP20220066T1 (https=)
HU (1) HUE057653T2 (https=)
LT (1) LT3230316T (https=)
PL (1) PL3230316T3 (https=)
PT (1) PT3230316T (https=)
RS (1) RS62827B1 (https=)
SI (1) SI3230316T1 (https=)
WO (1) WO2016094673A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007237096C1 (en) 2006-04-07 2012-12-13 EyePoint, Inc. Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof
AU2012323856B2 (en) 2011-10-13 2017-05-25 EyePoint, Inc. Methods for treating Vascular Leak Syndrome and cancer
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
PT3230316T (pt) 2014-12-11 2022-02-24 Bayer Healthcare Llc Ratamento de degenerescência macular relacionada com a idade com uma pequena lesão de neovascularização coroideia ativa
US10525035B2 (en) * 2014-12-18 2020-01-07 Lankenau Institute For Medical Research Methods and compositions for the treatment of retinopathy and other ocular diseases
KR102799807B1 (ko) 2015-12-30 2025-04-24 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
CN111699004A (zh) * 2018-02-06 2020-09-22 豪夫迈·罗氏有限公司 眼科疾病的治疗
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
US11103552B2 (en) 2018-05-10 2021-08-31 Regeneron Pharmaceuticals, Inc. High concentration VEGF receptor fusion protein containing formulations
CN120058958A (zh) 2018-09-24 2025-05-30 视点制药公司 靶向HPTP-β（VE-PTP）和VEGF的多特异性抗体
EP3873519A1 (en) 2018-10-29 2021-09-08 F. Hoffmann-La Roche AG Antibody formulation
CN118718181A (zh) 2019-06-05 2024-10-01 里珍纳龙药品有限公司 用于精确剂量递送的装置及方法
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
US11944663B2 (en) * 2020-06-18 2024-04-02 Chengdu Kanghong Biotechnologies Co. Ltd. Method for treating angiogenic eye disorders using VEGF antagonists
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
WO2025047970A1 (ja) * 2023-08-31 2025-03-06 国立大学法人京都大学 光感受性物質含有リポタンパク質、光線力学的療法用製剤、薬物デリバリー方法及び後眼部新生血管閉塞方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69735292T2 (de) 1996-10-25 2006-10-19 Gilead Sciences, Inc., Foster City Gefaesszellen wachstumsfaktor (vegf) nukleinsäureligand-komplexe
JP3957765B2 (ja) 1997-04-07 2007-08-15 ジェネンテク・インコーポレイテッド 抗ｖｅｇｆ抗体
CN100523187C (zh) 1999-06-08 2009-08-05 里珍纳龙药品有限公司 具有改善的药物动力学特性的修饰嵌合多肽
US8034803B2 (en) * 2001-02-06 2011-10-11 Qlt Inc. Photodynamic therapy of occult age-related macular degeneration
CN100502945C (zh) 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Vegf受体融合蛋白在治疗眼睛疾病中的应用
KR20260004598A (ko) * 2011-01-13 2026-01-08 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
PT3230316T (pt) 2014-12-11 2022-02-24 Bayer Healthcare Llc Ratamento de degenerescência macular relacionada com a idade com uma pequena lesão de neovascularização coroideia ativa

Also Published As

Publication number Publication date
AU2021245214B2 (en) 2024-05-02
CA2970315A1 (en) 2016-06-16
ES2907148T3 (es) 2022-04-22
CN106999511A (zh) 2017-08-01
HUE057653T2 (hu) 2022-05-28
EP3230316B1 (en) 2022-01-05
AU2015360496A1 (en) 2017-05-25
AU2021245214A1 (en) 2021-11-04
PL3230316T3 (pl) 2022-05-02
RS62827B1 (sr) 2022-02-28
US20170326106A1 (en) 2017-11-16
HRP20220066T1 (hr) 2022-04-15
LT3230316T (lt) 2022-02-10
US20190381008A1 (en) 2019-12-19
JP7320919B2 (ja) 2023-08-04
AU2024205237A1 (en) 2024-08-22
DK3230316T3 (da) 2022-03-28
EP3230316A1 (en) 2017-10-18
JP2017537117A (ja) 2017-12-14
JP2021004262A (ja) 2021-01-14
SI3230316T1 (sl) 2022-05-31
EP3985023A1 (en) 2022-04-20
AU2021107575A4 (en) 2022-01-06
CN112826934A (zh) 2021-05-25
CN114306575A (zh) 2022-04-12
CA2970315C (en) 2023-08-22
JP2022183183A (ja) 2022-12-08
WO2016094673A1 (en) 2016-06-16
AU2015360496B2 (en) 2021-09-30

Similar Documents

Publication Publication Date Title
HUE057653T2 (hu) Kis aktív choroidális neurovaszkularizáció lézióval jellemzett idõskori makuladegeneráció kezelése
IL265497B (en) Methods for treating eye diseases
IL252159A0 (en) Methods and formulations for the treatment of diseases of the blood vessels of the eye
IL253244A0 (en) Methods for treating retinal diseases
GB201403260D0 (en) Treatment of retinal degeneration using gene therapy
HUE041940T2 (hu) MRNS-terápia szembetegségek kezelésére
IL246791A0 (en) Compositions and methods for treating eye diseases
PT3658140T (pt) Combinações de aprocitentan com outros ingredientes ativos para o tratamento de hipertensão resistente
EP3122782A4 (en) Compositions and methods for treatment of diabetic macular edema
PL2953596T3 (pl) Technika fotodysrupcyjnej, wieloimpulsowej obróbki materiału
IL239736A0 (en) New pitfalls in the treatment of macular degeneration
ZA201704793B (en) Treatment of retinal degeneration using progenitor cells
SG11201607996SA (en) Effect of lipophilic nutrients on diabetic eye diseases
EP3089748A4 (en) Treating ocular neovascularization
SG11201608257RA (en) A device for a medical treatment of a sclera
IL247116A0 (en) Compositions and methods for treating and preventing macular degeneration
SI3509541T1 (sl) Leče za intrastromalno implantacijo roženice
EP3213762A4 (en) Novel treatment of cornea using laminin
GB201412578D0 (en) Treatment of neurological diseases
PL3233174T3 (pl) Wewnątrzgałkowe dostarczanie bioaktywnych cząsteczek za pomocą jontoforezy
IL261891A (en) Active retinal implant
IL252394A0 (en) Methods for preventing, reducing or treating macular degeneration
HK1230941A1 (en) Treating ocular neovascularization
GB201413330D0 (en) Agricultural treatment
GB201400839D0 (en) Agricultural treatment